Till Erdmann is co-founder of Berlin-based pharma start-up Myelo Therapeutics. It develops Myelo001, the first oral treatment for Chemotherapy-induced Neutropenia. Myelo001 is currently in clinical trials with breast cancer patients. It would be the first therapy innovation in over two decades to protect patients from one of the most frequent and most severe side effects of anticancer therapy.
Over the last two decades, Till got to know many facets confronting serious illnesses, as pharma industry management consultant, manager of a patient relationship program, founder of three life sciences start-ups, and family member of loved ones struggling with cancer. Till invented and launched the first virtual nurse visit program for Multiple Sclerosis patients via online video conferencing over 10 years ago and published research that showed it improved treatment adherence.
Till holds a degree in Industrial Engineering from Technical University of Berlin and a MBA from San Francisco State University. He loves to spend time with his Brazilian-German family, kitesurf, and play soccer.